Bilateral dual-energy contrast agent-enhanced digital mammography is as effective as MRI in detecting known primary breast tumors.
Bilateral dual-energy contrast agent-enhanced digital mammography is as effective as MRI in detecting known primary breast tumors and is more effective than conventional digital mammography, according to a study published in the December issue of the journal Radiology.
The small study began by testing the feasibility with 10 women who were newly diagnosed with breast cancer. They were injected with the imaging agent iohexol, dose of 1.5 mL per kg of body weight, and were imaged between 2.5 and 10 minutes following the injection. Following confirmation of the feasibility, the researchers enrolled 52 women with newly diagnosed breast cancer who had undergone previous MR imaging of the breast.
The results showed that the length of time between injection of the contrast and scanning did not affect the quality of the dual-energy contrast agent-enhanced (DE CE) digital mammography images, up to 10 minutes. Fifty-two index tumors were detected by both MR imaging and DE CE digital mammography, while only 42 were found by conventional mammography. The sizes of the tumors varied from 4 mm to 67 mm, with the median being 17 mm.
“DE CE digital mammography depicted 14 (56 percent) of 25 additional ipsilateral cancers compared with 22 (88 percent) of 25 for MR imaging,” wrote the authors.
The researchers did note that the DE CE digital mammography reported two false-positives, fewer than the 13 false-positives reported with the MR imaging.
The authors concluded that use of bilateral DE CE digital mammography was feasible and easy to accomplish, “with a lower sensitivity for detecting additional ipsilateral cancers than did MR imaging, but the specificity was higher.”
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.